RxDoctor Payments Data

Vinu Ganti, MD

Internal Medicine · Germantown, MDNPI 1760499826

Payments from drug & device makers

$17,422in general payments, 2019–2025

Across 949 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • GSK$977
  • Astellas Pharma US Inc$859
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,75096%
  • Education$6724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca99$2,038
AbbVie(2 entities)104$1,797
Novo Nordisk86$1,306
Lilly USA, LLC59$1,027
GSK60$977
Astellas Pharma US Inc29$859
Merck61$799
Bayer34$775
Vanda Pharmaceuticals Inc.40$658
Pfizer35$568
Amgen(2 entities)24$512
Boehringer Ingelheim28$504
Johnson & Johnson24$456
Novartis24$429
Eisai Inc.14$391
Abbott13$297
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$294
Gilead15$262
Exact Sciences11$242
Daiichi Sankyo Inc.13$226
Sunovion Pharmaceuticals Inc.13$212
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$181
Takeda Pharmaceuticals U.S.A., Inc.10$170
Amarin Pharma, Inc.8$127
Otsuka America Pharmaceutical, Inc.6$123
Lundbeck LLC6$123
Actelion Pharmaceuticals US, Inc.2$114
Ironwood Pharmaceuticals, Inc7$106
Lexicon Pharmaceuticals, Inc.4$103
Medtronic3$102
Sanofi-aventis U.S. LLC6$98
Boston Scientific1$93
Esperion Therapeutics, Inc.5$83
Xeris Pharmaceuticals, Inc.4$78
Mylan Specialty L.p.4$76
Noven Therapeutics, LLC3$74
Acadia Pharmaceuticals Inc3$68
Biohaven Pharmaceutical Holding Company Ltd.4$67
E.r. Squibb & Sons, L.L.C.4$66
Alfasigma USA, Inc.4$63
Avanir Pharmaceuticals, Inc.5$63
Idorsia Pharmaceuticals US Inc3$60
UCB, Inc.3$59
Currax Pharmaceuticals LLC4$56
Sumitomo Pharma America, Inc.3$54
Dexcom, Inc.2$51
Inspire Medical Systems, Inc.1$44
IBSA Pharma Inc.2$42
Hikma Pharmaceuticals USA3$42
Genentech USA, Inc.2$38
Nevro Corp.1$37
Kowa Pharmaceuticals America, Inc.2$31
Baxter Healthcare1$30
Viiv Healthcare Company2$29
Almatica Pharma LLC1$27
Sanofi Pasteur Inc.1$23
Azurity Pharmaceuticals, Inc.1$23
Optinose US, Inc.1$22
Avion Pharmaceuticals1$22
Nalpropion Pharmaceuticals LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,422 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$634,505
Medicare patients
1,019
Services billed
7,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban560$300,386
JardianceEmpagliflozin246$269,075
OzempicSemaglutide116$207,520
GenvoyaElviteg/Cob/Emtri/Tenof Alafen34$146,912
TradjentaLinagliptin160$138,607
JanuviaSitagliptin Phosphate146$96,588
BiktarvyBictegrav/Emtricit/Tenofov Ala22$90,490
FarxigaDapagliflozin Propanediol104$85,899
JanumetSitagliptin Phos/Metformin Hcl73$82,846
TrulicityDulaglutide100$70,708
XareltoRivaroxaban146$66,813
MounjaroTirzepatide40$59,648
ArexvyRsvpref3 Antigen/As01e/Pf196$59,108
LinzessLinaclotide49$55,928
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$55,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$504$407,682406 claims
PfizerEliquis$568$300,386560 claims
GileadGenvoya, Biktarvy$262$237,40256 claims
Novo NordiskOzempic, Rybelsus$1,306$232,619131 claims
MerckJanuvia, Janumet, Janumet Xr$799$196,206241 claims
GSKArexvy, Trelegy Ellipta, Breo Ellipta$977$135,083282 claims
Lilly USA, LLCTrulicity, Mounjaro$1,027$130,356140 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$2,038$121,224180 claims
Johnson & JohnsonXarelto$456$66,813146 claims
AbbVieLinzess$1,797$55,92849 claims
Astellas Pharma US IncMyrbetriq$859$34,89380 claims
NovartisEntresto$429$33,61463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →